この記事を読む

EGFR-TKI耐性後の免疫治療 vs 殺細胞性抗がん剤

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EG…

この記事を読む

MET14skippingのテポチニブ治療は背景に依存するか

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION…

この記事を読む

SP142と22C3:同じか異なるのか

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell L…

この記事を読む

EGFR遺伝子変異陽性、切除後の予後は

Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM…

この記事を読む

EGFR遺伝子変異陽性の術後補助化学療法の層別化

Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small C…

この記事を読む

腫瘍サイズと免疫チェックポイント阻害薬

The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with …

この記事を読む

EGFR遺伝子変異陽性、手術追加の意義は?

Thoracic surgery improved overall survival in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung a…

この記事を読む

非扁平上皮癌の方がPD-L1発現とOSが相関しやすい?

Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Non…

この記事を読む

アファチニブ→オシメルチニブの治療シークエンス

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-inter…

この記事を読む

いわゆるオリゴメタに対する外科治療

The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cance…